Global pharma major Roche today said it has launched monoclonal antibody atezolizumab under the brand name Tecentriq in India for treatment of lung and bladder cancer.
Tecentriq has shown to extend survival and improve the quality of life in the approved indications, Roche said in a statement.
The product has been approved in India "for two types of cancers: non-small cell lung cancer (NSCLC) and Urothelial Carcinoma, a type of bladder and urinary tract cancer", it added.
The drug will now be available to patients in India on the prescription of oncologists, Roche said.
Commenting on the development, Roche Products India Pvt Ltd MD Lara Bezerra said: "Bringing Tecentriq to India reflects Roche's commitment to bring global innovations to the country."
Disclaimer: No Business Standard Journalist was involved in creation of this content